Fexofenadine

Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[1][2][3].

Product Specifications

CAS Number

[83799-24-0]

Product Name Alternative

MDL-16455; Terfenadine carboxylate

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/fexofenadine.html

Purity

99.84

Solubility

10 mM in DMSO

Smiles

OC(C1=CC=CC=C1)(C2=CC=CC=C2)C3CCN(CCCC(C4=CC=C(C(C(O)=O)(C)C)C=C4)O)CC3

Molecular Formula

C32H39NO4

Molecular Weight

501.66

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Watanabe N, et al. The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralis. Int Immunopharmacol. 2004 Mar;4 (3) :367-75.|[2]Park IH, et al. Histamine Promotes the Release of Interleukin-6 via the H1R/p38 and NF-κB Pathways in Nasal Fibroblasts. Allergy Asthma Immunol Res. 2014 Nov;6 (6) :567-72.|[3]Ming X, et al. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol Pharm. 2011 Oct 3;8 (5) :1677-86.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

H1 Receptor

Citation 01

Adv Mater Technol. 2023 Jan 29.|Biomed Pharmacother. 2024 Jun:175:116644.|Pharmacol Res. 2023 Apr:190:106724.|Drug Metab Dispos. 2025 Mar;53 (3) :100046.|Int Immunopharmacol. 2023 Mar:116:109637.